Effects of an inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 inhibitor on energy balance and glucose homeostasis in diet-induced obesity

被引：0

作者：

Arch, JRS

Wang, SJY

Birtles, S

Smith, DM

Turnbull, A

机构：

[1] Univ Buckingham, Clore Lab, Buckingham, England

[2] AstraZeneca, Macclesfield, Cheshire, England

来源：

DIABETOLOGIA | 2005年 / 48卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

650

引用

页码：A238 / A238

页数：1

共 50 条

[21] THE 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 MRNA LEVELS ARE NOT ASSOCIATED WITH AGE IN OSTEOARTHRITIS PATIENTS
Wolff, F.
Nijs-de Wolf, N.
Willems, D.
Demulder, A.
Lamraski, G.
Putz, P.
Bergmann, P.
OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 91 - 91
[22] 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis, Panagiotis
Katsiki, Niki
Adamidou, Fotini
Athyros, Vasilios G.
Karagiannis, Asterios
Kita, Marina
Mikhailidis, Dimitri P.
METABOLISM-CLINICAL AND EXPERIMENTAL, 2013, 62 (01): : 21 - 33
[23] HIS-388, a potent orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, improves insulin resistance and glucose intolerance in obese and diabetes model mice.
Okazaki, Seiji
Iwamura, Tomokatsu
Takahashi, Takehiro
Nakaki, Junko
Sekiya, Yumiko
Kumagai, Hiroki
Sakami, Satoshi
Nitta, Aiko
Kawai, Koji
Kainoh, Mie
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2012, 118 : 254P - 254P
[24] HIS-388, a Novel Orally Active and Long-Acting 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, Ameliorates Insulin Sensitivity and Glucose Intolerance in Diet-Induced Obesity and Nongenetic Type 2 Diabetic Murine Models
Okazaki, Seiji
Takahashi, Takehiro
Iwamura, Tomokatsu
Nakaki, Junko
Sekiya, Yumiko
Yagi, Mai
Kumagai, Hiroki
Sato, Mikiya
Sakami, Satoshi
Nitta, Aiko
Kawai, Koji
Kainoh, Mie
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 351 (01): : 181 - 189
[25] Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity
Susanna Bianzano
Tim Heise
Arvid Jungnik
Cornelia Schepers
Corinna Schölch
Ulrike Gräfe-Mody
Clinical Diabetes and Endocrinology, 7 (1):
[26] Structural characterization and pharmacodynamic effects of an orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor
Hale, Clarence
Veniant, Murielle
Wang, Zhulun
Chen, Michelle
McCormick, Jocelyn
Cupples, Rod
Hickman, Dean
Min, Xiaoshan
Sudom, Athena
Xu, Haoda
Matsumoto, Guy
Fotsch, Christopher
Jean, David J., Jr.
Wang, Minghan
CHEMICAL BIOLOGY & DRUG DESIGN, 2008, 71 (01) : 36 - 44
[27] Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone
Sandeep, TC
Andrew, R
Homer, NZM
Andrews, RC
Smith, K
Walker, BR
DIABETES, 2005, 54 (03) : 872 - 879
[28] Regulation of 11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Expression in the Rat Heart by Androgens.
Kienitz, T.
Michaelis, M.
Hofmann, P.
Gotz, F.
Quinkler, M.
ENDOCRINE REVIEWS, 2010, 31 (03)
[29] Glucocorticoid activation by 11beta-hydroxysteroid dehydrogenase type 1:: A novel pharmacological target in the metabolic syndrome
Oppermann, U
Hult, M
Shafqat, N
Elleby, B
Svensson, S
Vallgårda, J
Abrahmsen, L
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2003, 367 : R13 - R13
[30] Safety and Efficacy of BI 187004, a Selective 11beta-Hydroxysteroid Dehydrogenase 1 (11b-HSD1) Inhibitor, after 4 Weeks of Treatment in Patients with Type 2 Diabetes
Freude, Susanna
Heise, Tim
Nordaby, Matias
Peil, Barbara
Zeller, Cordula
Wolff, Michael
Sabo, John P.
Vernillet, Laurent
Woerle, Hans-Juergen
Graefe-Mody, Ulrike
DIABETES, 2016, 65 : A312 - A312

← 1 2 3 4 5 →